Biosimilar-to-Biosimilar Switches Deemed Safe, Effective

While switches between biosimilars of the same reference biologic already occur for biosimilars with indications in different specialties, they do not meet regulators' interchangeability standards.

Related Keywords

New York ,United States ,California ,New Haven ,Connecticut ,Stanford School ,Ohio ,Texas ,Rajat Bhatt ,Miguel Regueiro ,Jeffrey Weinberg ,Keith Choate ,Jean Frederic Colombel ,Hillelp Cohen ,Eli Lilly ,Stanford Shoor ,Florence Aslinia ,Alfred Kim ,Glaxosmithkline ,Yale School Of Medicine ,Stanford School Of Medicine ,Washington University School Of Medicine ,Novartis ,University Of Kansas Health System ,Pfizer ,Caribbean Medical University ,Astrazeneca ,Icahn School Of Medicine At Mount Sinai ,Digestive Disease Surgery Institute ,Medscape Medical ,Icahn School ,Mount Sinai ,New York City ,Medscape Medical News ,Yale School ,Digestive Disease ,Surgery Institute ,Cleveland Clinic ,Prime Rheumatology ,Barnes Jewish Hospital ,Washington University School ,Kansas Health System ,Biologic Therapy ,Biosimilars ,Biosimilar Drugs ,Follow On Biologics ,Medical Literature ,Books ,Textbooks ,Ournals ,Clinical Research ,Clinical Trials ,Linical Studies ,